This article presents analyzed data on new diagnoses and mortality of breast cancer, between 2005 and 2013, in the Republic of Cyprus. New diagnoses are presented by demographic and clinical/histological variables that include cancer grade, behaviour, stage, and histological type at diagnosis (always as a primary site). Breast cancer-related deaths are presented by gender. Net survival rates based on cohort and period methods are presented by age group, cancer grade, behaviour, and stage at diagnosis, for all cases and for cases of Greek-Cypriot ethnicity. The unprocessed data of the Cyprus Cancer Registry were provided by the Health Monitoring Unit of the Ministry of Health of the Republic of Cyprus.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* Corresponding author.
E-mail addresses: nikolopoulos.georgios@ucy.ac.cy, gknikolopoulos@gmail.com (G.K. Nikolopoulos).
1. Data

This article includes analyzed data on breast cancer cases obtained from the Cyprus Cancer Registry in the Health Monitoring Unit of the Ministry of Health of the Republic of Cyprus for the period 2005–2013. Demographic and clinical/histological parameters of newly diagnosed breast cancer cases are shown in Tables 1–5. Table 6 presents the classification of histological types and their subtypes (always as primary sites) used for the analysis of data. Breast cancer mortality per year can be found in Table 7. Net survival rates for breast cancer (Tables 8–15) are presented for 2004–2008 and 2009–2013.

Table 1 shows counts and percentages of newly diagnosed breast cancer cases by gender, age, ethnicity (Greek-Cypriot/Non-Greek-Cypriot/Unknown), marital status at the time of diagnosis (single/married/divorced or separated/widowed/unknown), smoking history at the time of diagnosis (yes/no/unknown), and patients’ birthplace (Cyprus districts) as well as the median and the interquartile range (IQR) of patients’ age. Tables 2–5 present counts and percentages of newly diagnosed breast cancer cases by cancer grade (well differentiated/moderately differentiated/poorly differentiated/undifferentiated/unknown), behaviour (in situ/invasive), stage (distant metastatic/in situ/locoregional invasive/unknown), and histological type at diagnosis (adenoid cystic carcinoma/carcinoma with apocrine features/carcinoma with medullary features/cribriform carcinoma/inflammatory carcinoma/invasive carcinoma of no special type/invasive lobular carcinoma/mesenchymal tumours/metaplastic carcinoma/mucinous carcinoma/Paget’s disease/phyllodes tumour/rare variants/tubular carcinoma). Cases are also presented by ethnicity (Greek-Cypriot and Non-Greek-Cypriot). Armenians and Maronites belong to the Greek-Cypriot community but represent different ethnic/religious groups and given their small numbers were included along with the European Union (EU) foreigners and the non-EU foreigners in the non-Greek-Cypriot group. The ethnicity group “Unknown” is omitted. Subtypes of breast cancer classified in the categories of histological type used in the analysis are presented in Table 6. Table 7 gives breast cancer-related deaths by gender. Tables 8–15 show five-year net survival rates of breast cancer cases, based on cohort and period approaches, for 2004–2008 and 2009–2013, by age group, cancer stage, grade, and behaviour at diagnosis for all recorded cases (Tables 8–11) and for Greek-Cypriots only (Tables 12–15).

2. Experimental design, materials and methods

The data presented in this article were obtained from the Cyprus Cancer Registry and the Causes of Death Registry in the Health Monitoring Unit at the Ministry of Health of the Republic of Cyprus. The
Table 1
Demographic characteristics of newly diagnosed breast cancer cases (N = 4769) by year of diagnosis (2005–2013).

| Gender | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total  |
|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| N (%)  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  |        |
| Female | 452 (98.9) | 433 (98.2) | 535 (98.9) | 510 (98.5) | 476 (99.2) | 549 (99.5) | 602 (99.2) | 562 (99.1) | 603 (99.5) | 4722 (99.0) |
| Male   | 5 (1.1) | 8 (1.8) | 6 (1.1) | 8 (1.5) | 4 (0.8) | 3 (0.5) | 5 (0.8) | 5 (0.9) | 3 (0.5) | 47 (1.0) |
| Age    | 57 (46–67) | 58 (47–68) | 58 (48–68) | 58 (49–69) | 59 (49–68) | 59 (49–69) | 60 (50–69) | 60 (50–69) | 59 (49–59) |

| Ethnicity | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total  |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| Greek-Cypriot | 398 (87.1) | 372 (84.4) | 460 (85.0) | 435 (84.0) | 411 (85.6) | 467 (84.6) | 508 (83.7) | 475 (83.8) | 524 (86.5) | 4050 (85.0) |
| Non-Greek-Cypriot a | 59 (12.9) | 65 (14.7) | 76 (14.1) | 77 (14.9) | 65 (13.6) | 81 (14.7) | 83 (13.7) | 73 (12.9) | 71 (11.7) | 650 (13.6) |
| Unknown    | 0 (0.0) | 5 (0.9) | 6 (1.1) | 8 (1.6) | 11 (2.2) | 23 (4.0) | 29 (4.9) | 30 (5.1) | 27 (4.5) | 150 (3.2) |

| Marital Status | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total  |
|----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| Single         | 31 (6.8) | 23 (5.2) | 28 (5.2) | 26 (5.0) | 26 (5.4) | 30 (5.4) | 38 (6.3) | 34 (6.0) | 31 (5.1) | 267 (5.6) |
| Married        | 307 (67.2) | 298 (67.6) | 383 (70.8) | 369 (71.3) | 348 (72.5) | 383 (69.4) | 410 (67.5) | 361 (63.7) | 399 (65.9) | 3258 (68.3) |
| Divorced/Separated | 22 (4.8) | 32 (7.2) | 34 (6.3) | 25 (4.8) | 21 (4.4) | 27 (4.9) | 32 (5.3) | 43 (7.6) | 36 (5.9) | 272 (5.7) |
| Widowed        | 57 (12.5) | 59 (13.4) | 61 (11.3) | 57 (11.0) | 61 (11.2) | 66 (11.9) | 64 (11.3) | 60 (9.9) | 532 (11.2) |
| Unknown        | 40 (8.7) | 29 (6.6) | 35 (6.4) | 41 (7.9) | 39 (8.1) | 50 (9.1) | 61 (10.0) | 65 (11.4) | 80 (13.2) | 440 (9.2) |

| Smoking History | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total  |
|-----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| Yes             | 45 (9.8) | 54 (12.2) | 82 (15.2) | 60 (11.6) | 34 (7.1) | 65 (11.8) | 80 (13.2) | 83 (14.6) | 59 (9.7) | 562 (11.8) |
| No              | 164 (35.9) | 137 (31.1) | 188 (34.7) | 213 (41.1) | 214 (44.6) | 243 (44.0) | 259 (42.7) | 247 (43.6) | 241 (39.8) | 1906 (40.0) |
| Unknown         | 248 (54.3) | 250 (56.7) | 271 (50.1) | 245 (47.3) | 232 (48.3) | 244 (44.2) | 268 (44.1) | 237 (41.8) | 306 (50.5) | 2301 (48.2) |

| Birthplace b | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total  |
|--------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| Ammochostos  | 71 (15.5) | 57 (12.9) | 92 (17.0) | 61 (11.8) | 92 (19.2) | 66 (12.0) | 95 (15.6) | 76 (13.4) | 92 (15.2) | 701 (14.7) |
| Kyrenia      | 18 (3.9) | 16 (3.6) | 34 (6.3) | 12 (2.3) | 13 (2.7) | 20 (3.6) | 20 (3.3) | 18 (3.2) | 19 (3.1) | 170 (3.6) |
| Larnaca      | 43 (9.4) | 32 (7.3) | 43 (8.0) | 30 (5.8) | 37 (7.7) | 35 (6.3) | 42 (6.9) | 45 (7.9) | 50 (8.3) | 357 (7.5) |
| Nicosia      | 118 (25.8) | 130 (29.5) | 143 (26.4) | 157 (30.3) | 147 (30.6) | 174 (31.5) | 173 (28.5) | 177 (31.2) | 200 (33.0) | 1419 (29.8) |
| Limassol     | 66 (14.4) | 56 (12.7) | 79 (14.6) | 81 (15.6) | 59 (12.3) | 68 (12.3) | 83 (13.7) | 72 (12.7) | 72 (11.9) | 636 (13.3) |
| Pafos        | 35 (7.7) | 37 (7.5) | 30 (5.6) | 36 (7.0) | 27 (5.6) | 47 (8.5) | 42 (6.9) | 27 (4.8) | 31 (5.1) | 308 (6.5) |
| Unknown      | 106 (23.3) | 117 (26.5) | 120 (22.1) | 141 (27.2) | 105 (21.9) | 142 (25.8) | 153 (25.2) | 152 (26.8) | 142 (23.4) | 1178 (24.6) |

a Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

b Birthplace refers to one of the six districts of the Republic of Cyprus.
Table 2
Cancer grade of newly diagnosed breast cancer cases (N = 4700) by ethnicity and year of diagnosis (2005–2013).

| Cancer grade        | 2005   | 2006   | 2007   | 2008   | 2009   | 2010   | 2011   | 2012   | 2013   | Total  |
|---------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Greek-Cypriot [N (%)] |        |        |        |        |        |        |        |        |        |        |
| I; Well Differentiated | 32 (8.0) | 36 (9.7) | 59 (12.8) | 33 (7.6) | 35 (8.5) | 36 (7.7) | 28 (5.5) | 38 (8.0) | 30 (5.7) | 327 (8.1) |
| II; Moderately       | 181 (45.5) | 161 (43.3) | 200 (43.5) | 173 (39.8) | 182 (44.3) | 205 (43.9) | 236 (46.5) | 209 (44.0) | 264 (50.4) | 1811 (44.7) |
| Differentiated       |         |        |        |        |        |        |        |        |        |        |
| III; Poorly          | 97 (24.4) | 98 (26.3) | 110 (23.9) | 159 (36.5) | 135 (32.8) | 144 (30.8) | 160 (31.5) | 163 (34.3) | 143 (27.3) | 1209 (29.8) |
| Differentiated       |         |        |        |        |        |        |        |        |        |        |
| Undifferentated/     | 88 (22.1) | 77 (20.7) | 91 (19.8) | 70 (16.1) | 59 (14.4) | 82 (17.6) | 84 (16.5) | 65 (13.7) | 87 (16.6) | 703 (17.4) |
| Unknown              |         |        |        |        |        |        |        |        |        |        |
| Non-Greek-          | 3 (5.1) | 3 (4.6) | 2 (2.6) | 5 (6.4) | 2 (3.1) | 4 (4.9) | 1 (1.2) | 4 (5.5) | 3 (4.2) | 27 (4.2) |
| Cypriot [N (%)]      | 30 (50.9) | 25 (38.5) | 29 (38.2) | 32 (41.6) | 28 (43.1) | 38 (46.9) | 41 (49.4) | 30 (41.1) | 29 (40.8) | 282 (43.4) |
| I; Well Differentiated|         |        |        |        |        |        |        |        |        |        |
| II; Moderately       | 11 (18.6) | 23 (35.4) | 26 (34.2) | 32 (41.6) | 30 (46.1) | 27 (33.4) | 33 (39.8) | 30 (41.1) | 33 (46.5) | 245 (37.7) |
| Differentiated       |         |        |        |        |        |        |        |        |        |        |
| III; Poorly          | 15 (25.4) | 14 (21.5) | 19 (25.0) | 8 (10.4) | 5 (7.7) | 12 (14.8) | 8 (9.6) | 9 (12.3) | 6 (8.5) | 96 (14.7) |
| Differentiated       |         |        |        |        |        |        |        |        |        |        |
| Undifferentated/     |         |        |        |        |        |        |        |        |        |        |
| Unknown              |         |        |        |        |        |        |        |        |        |        |
| Total [N (%)]        | 35 (7.7) | 39 (8.9) | 61 (11.4) | 38 (7.4) | 37 (7.8) | 40 (7.3) | 29 (4.9) | 42 (7.7) | 33 (5.6) | 354 (7.5) |
| I; Well Differentiated| 211 (46.2) | 186 (42.6) | 229 (42.7) | 205 (40.0) | 210 (44.1) | 243 (44.2) | 277 (46.9) | 239 (43.5) | 293 (49.2) | 2093 (44.5) |
| II; Moderately       |         |        |        |        |        |        |        |        |        |        |
| Differentiated       | 108 (23.6) | 121 (27.7) | 136 (25.4) | 191 (37.4) | 165 (34.7) | 171 (31.3) | 193 (35.3) | 176 (29.6) | 1454 (30.9) |
| III; Poorly          | 103 (22.5) | 91 (20.8) | 110 (20.5) | 78 (15.2) | 64 (13.4) | 94 (17.2) | 92 (15.6) | 74 (13.5) | 93 (15.6) | 799 (17.0) |
| Differentiated       |         |        |        |        |        |        |        |        |        |        |
| Undifferentated/     |         |        |        |        |        |        |        |        |        |        |
| Unknown              |         |        |        |        |        |        |        |        |        |        |

* Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.
Table 3
Cancer behaviour of newly diagnosed breast cancer cases (N = 4700) by ethnicity and year of diagnosis (2005–2013).

| Cancer behaviour  | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | Total |
|-------------------|------|------|------|------|------|------|------|------|------|-------|
| **Greek-Cypriot [N (%)]** |      |      |      |      |      |      |      |      |      |       |
| In situ           | 33   | 19   | 48   | 42   | 39   | 43   | 47   | 38   | 57   | 366   |
|                   | (8.3)| (5.1)| (10.4)| (9.7)| (9.5)| (9.2)| (9.2)| (8.0)| (10.9)| (9.0) |
| Invasive          | 365  | 353  | 412  | 393  | 372  | 424  | 461  | 437  | 468  | 3685  |
|                   | (91.7)| (94.9)| (89.6)| (90.3)| (90.5)| (90.8)| (90.8)| (92.0)| (89.1)| (91.0) |
| **Non-Greek-Cypriot [N (%)]** |      |      |      |      |      |      |      |      |      |       |
| In situ           | 5    | 2    | 5    | 2    | 1    | 6    | 2    | 4    | 2    | 29    |
|                   | (8.5)| (3.1)| (6.6)| (2.6)| (1.5)| (7.4)| (2.4)| (5.5)| (2.8)| (4.5) |
| Invasive          | 54   | 63   | 71   | 75   | 64   | 75   | 81   | 69   | 69   | 621   |
|                   | (91.5)| (96.9)| (93.4)| (97.4)| (98.5)| (92.6)| (97.6)| (94.5)| (97.2)| (95.5) |
| **Total [N (%)]** |      |      |      |      |      |      |      |      |      |       |
| In situ           | 38   | 21   | 53   | 44   | 49   | 49   | 42   | 59   | 395  | 8.4   |
|                   | (8.3)| (4.8)| (9.9)| (8.6)| (8.9)| (8.3)| (7.7)| (9.7)| (9.7)|       |
| Invasive          | 419  | 416  | 483  | 468  | 499  | 542  | 506  | 537  | 4306 |       |
|                   | (91.7)| (95.2)| (90.1)| (91.4)| (91.1)| (91.7)| (92.3)| (90.3)| (91.6)|       |

* Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.
Table 4
Cancer stage of newly diagnosed breast cancer cases (N = 4700) by ethnicity and year of diagnosis (2005–2013).

| Cancer stage                  | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | Total |
|-------------------------------|------|------|------|------|------|------|------|------|------|-------|
| **Greek-Cypriot [N (%)]**     |      |      |      |      |      |      |      |      |      |       |
| Distant metastatic            | 16 (4.0) | 17 (4.6) | 25 (5.4) | 23 (5.3) | 18 (4.4) | 17 (3.6) | 19 (3.7) | 15 (3.2) | 9 (1.7) | 159 (3.9) |
| In situ                       | 33 (8.3) | 19 (5.1) | 48 (10.5) | 42 (9.7) | 39 (9.5) | 43 (9.2) | 47 (9.3) | 38 (8.0) | 57 (10.9) | 366 (9.0) |
| Locoregional invasive         | 320 (80.4) | 302 (81.2) | 340 (73.9) | 328 (75.4) | 315 (76.6) | 353 (75.6) | 383 (75.4) | 365 (76.8) | 396 (75.6) | 3102 (76.6) |
| Unknown                       | 29 (7.3) | 34 (9.1) | 47 (10.2) | 42 (9.6) | 39 (9.5) | 54 (11.6) | 59 (11.6) | 57 (12.0) | 62 (11.8) | 423 (10.4) |
| **Non-Greek-Cypriot [N (%)]** |      |      |      |      |      |      |      |      |      |       |
| Distant metastatic            | 1 (1.7) | 3 (4.6) | 4 (5.3) | 5 (6.5) | 3 (4.6) | 6 (7.4) | 2 (2.4) | 6 (8.2) | 2 (2.8) | 32 (5.0) |
| In situ                       | 5 (8.5) | 2 (3.1) | 5 (6.6) | 2 (2.6) | 1 (1.5) | 6 (7.4) | 2 (2.4) | 4 (5.5) | 2 (2.8) | 29 (4.5) |
| Locoregional invasive         | 49 (83.0) | 55 (84.6) | 57 (75.0) | 60 (77.9) | 51 (78.5) | 64 (79.0) | 67 (80.7) | 54 (74.0) | 55 (77.5) | 512 (78.8) |
| Unknown                       | 4 (6.8) | 5 (7.7) | 10 (13.1) | 10 (15.4) | 5 (6.2) | 12 (14.5) | 9 (12.3) | 12 (16.9) | 77 (11.7) |       |
| **Total [N (%)]**             |      |      |      |      |      |      |      |      |      |       |
| Distant metastatic            | 17 (3.7) | 20 (4.6) | 29 (5.4) | 28 (5.5) | 21 (4.4) | 23 (4.2) | 21 (3.6) | 21 (3.8) | 11 (1.9) | 191 (4.1) |
| In situ                       | 38 (8.3) | 21 (4.8) | 53 (9.9) | 44 (8.6) | 40 (8.4) | 49 (8.9) | 49 (8.3) | 42 (7.7) | 59 (9.9) | 395 (8.4) |
| Locoregional invasive         | 369 (80.8) | 357 (81.7) | 397 (74.1) | 388 (75.7) | 366 (76.9) | 417 (76.1) | 450 (76.1) | 419 (76.5) | 451 (75.8) | 3614 (76.9) |
| Unknown                       | 33 (7.2) | 39 (8.9) | 57 (10.6) | 52 (10.2) | 49 (10.3) | 59 (10.8) | 71 (12.0) | 66 (12.0) | 74 (12.4) | 500 (10.6) |

* Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.
| Histologic morphological type | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | Total |
|-----------------------------|------|------|------|------|------|------|------|------|------|-------|
| **Greek-Cypriot [N (%)]**   |      |      |      |      |      |      |      |      |      |       |
| Adenoid cystic carcinoma    | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) |
| Carcinoma with apocrine features | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 3 (0.1) |
| Carcinoma with medullary features | 2 (0.5) | 1 (0.3) | 3 (0.7) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.4) | 9 (0.2) |
| Cribriform carcinoma        | 0 (0.0) | 0 (0.0) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.4) | 5 (0.1) |
| Inflammatory carcinoma      | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) |
| Invasive carcinoma of no special type | 291 (73.1) | 256 (68.8) | 338 (73.5) | 354 (81.4) | 328 (79.8) | 353 (75.6) | 406 (79.9) | 381 (80.2) | 416 (79.4) | 3123 (77.1) |
| Invasive lobular carcinoma  | 42 (10.5) | 50 (13.4) | 41 (8.9) | 38 (8.7) | 51 (12.4) | 56 (12.0) | 49 (9.7) | 58 (12.2) | 60 (11.5) | 445 (11.0) |
| Mesenchymal tumours         | 0 (0.0) | 0 (0.0) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) |
| Metaplastic carcinoma       | 7 (1.8) | 6 (1.6) | 12 (2.6) | 8 (1.8) | 1 (0.2) | 9 (1.9) | 4 (0.8) | 1 (0.2) | 0 (0.0) | 7 (0.2) |
| Mucinous carcinoma          | 2 (0.5) | 3 (0.8) | 2 (0.4) | 1 (0.2) | 2 (0.4) | 2 (0.4) | 3 (0.6) | 2 (0.4) | 2 (0.4) | 19 (0.5) |
| Paget's disease             | 3 (0.7) | 2 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) |
| Rare variants               | 42 (10.6) | 48 (12.8) | 47 (10.3) | 28 (6.4) | 22 (5.4) | 37 (7.9) | 37 (7.3) | 21 (4.4) | 24 (4.5) | 306 (7.5) |
| Tubular carcinoma           | 9 (2.3) | 6 (1.6) | 8 (1.8) | 5 (1.3) | 6 (1.5) | 6 (1.4) | 5 (0.9) | 2 (0.5) | 4 (0.7) | 51 (1.2) |
| **Non-Greek-Cypriot [N (%)]** |      |      |      |      |      |      |      |      |      |       |
| Adenoid cystic carcinoma    | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Carcinoma with apocrine features | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
| Carcinoma with medullary features | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.3) |
| Cribriform carcinoma        | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Inflammatory carcinoma      | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
| Invasive carcinoma of no special type | 50 (84.8) | 57 (87.7) | 59 (77.6) | 60 (77.9) | 51 (78.5) | 69 (85.2) | 72 (86.8) | 63 (86.3) | 56 (78.9) | 537 (82.5) |
| Invasive lobular carcinoma  | 6 (10.1) | 4 (6.1) | 5 (6.7) | 10 (13.0) | 7 (10.8) | 6 (7.5) | 4 (4.8) | 5 (6.8) | 8 (11.3) | 55 (8.4) |
| Mesenchymal tumours         | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Metaplastic carcinoma       | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
| Mucinous carcinoma          | 1 (1.7) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 2 (3.1) | 1 (1.2) | 0 (0.0) | 1 (1.4) | 3 (4.2) |
| Paget's disease             | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) | 1 (1.2) | 1 (1.4) | 0 (0.0) | 3 (0.5) |
| Phyllodes tumour            | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
| Rare variants               | 2 (3.4) | 4 (6.2) | 8 (10.5) | 5 (6.5) | 3 (4.6) | 4 (4.9) | 6 (7.2) | 3 (4.1) | 3 (4.2) | 38 (5.8) |
| Tubular carcinoma           | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 2 (0.3) |       |
Table 5 (continued)

| Histologic morphological type | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | Total |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Adenoid cystic carcinoma     | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) |
| Carcinoma with apocrine features | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 4 (0.1) |
| Carcinoma with medullary features | 2 (0.4) | 1 (0.2) | 4 (0.7) | 0 (0.0) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.3) | 11 (0.2) |
| Cribriform carcinoma         | 0 (0.0) | 0 (0.0) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.3) | 5 (0.1) |
| Inflammatory carcinoma       | 0 (0.0) | 0 (0.0) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.0) | 11 (0.2) |
| Invasive carcinoma of no special type | 341 (74.6) | 313 (71.6) | 397 (74.1) | 414 (80.9) | 379 (74.1) | 422 (77.0) | 478 (80.9) | 444 (81.0) | 482 (79.5) | 3660 (77.9) |
| Invasive lobular carcinoma   | 48 (10.5) | 54 (12.3) | 46 (8.5) | 48 (9.3) | 58 (12.2) | 62 (11.2) | 53 (9.9) | 63 (11.4) | 68 (11.3) | 500 (10.7) |
| Mesenchymal tumours          | 0 (0.0) | 0 (0.0) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 2 (0.3) | 3 (0.6) |
| Metaplastic carcinoma        | 0 (0.0) | 0 (0.0) | 2 (0.4) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 4 (0.7) | 1 (0.2) | 0 (0.0) | 8 (0.2) |
| Mucinous carcinoma           | 8 (1.8) | 6 (1.4) | 13 (2.4) | 8 (1.5) | 3 (0.6) | 10 (1.8) | 4 (0.7) | 9 (1.6) | 15 (2.5) | 76 (1.6) |
| Paget's disease              | 2 (0.4) | 3 (0.7) | 2 (0.4) | 1 (0.2) | 2 (0.4) | 3 (0.6) | 4 (0.7) | 3 (0.6) | 2 (0.3) | 22 (0.5) |
| Phylloides tumour            | 3 (0.7) | 2 (0.5) | 3 (0.6) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 2 (0.2) | 11 (0.2) |
| Rare variants                | 44 (9.6) | 52 (11.9) | 55 (10.2) | 33 (6.5) | 25 (5.3) | 41 (7.5) | 43 (7.2) | 24 (4.4) | 28 (4.6) | 344 (7.3) |
| Tubular carcinoma            | 9 (2.0) | 6 (1.4) | 8 (1.5) | 6 (1.2) | 6 (1.3) | 6 (1.1) | 5 (0.9) | 2 (0.4) | 5 (0.8) | 53 (1.1) |

* Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.
Cyprus Cancer Registry collects data from all public and private hospitals as well as from clinics within the Republic of Cyprus [1]. It was established in the context of the Middle East Cancer Consortium (MECC) Cancer Registry Project opened on 1st January 1998 aiming to standardize data items, definitions, and codes in order to ensure reliable comparisons. The reference date of diagnoses that are included in MECC for Cyprus is January 1, 1998. MECC is an intergovernmental organization established in 1996 in Geneva, Switzerland, by an agreement between Cyprus, Egypt, Israel, Jordan, and the Palestinian Authority. The aim of MECC is to raise cancer awareness and reduce the burden of cancer in Middle East [1].

The data in this article refer to the period between 2005 and 2013. The unprocessed data provided by the Health Monitoring Unit at the Ministry of Health were checked for duplicates. Duplicates were deleted from the dataset. Only patients residing in the controlled area by the Republic of Cyprus were included.

Overall, between 2005 and 2013, 4769 newly diagnosed breast cancer cases residing in the Republic of Cyprus were recorded in the Cyprus Cancer Registry. Their demographic characteristics (gender, age, ethnicity, marital status, smoking history, and birthplace) are presented in Table 1. The

### Table 6

| Histologic type                          | ICD-O-3 morphology code |
|-----------------------------------------|-------------------------|
| Adenoid cystic carcinoma                | 8200/3                  |
| Carcinoma with apocrine features        | 8401/3                  |
| Carcinoma with medullary features       |                         |
| Atypical medullary carcinoma            | 8513/3                  |
| Medullary carcinoma, NOS                | 8510/3                  |
| Cribriform carcinoma                    | 8201/3                  |
| Inflammatory carcinoma                  | 8530/3                  |
| Invasive carcinoma of no special type   |                         |
| Duct carcinoma                          | 8500/3                  |
| Infiltrating duct mixed with other types of carcinoma | 8523/3 |
| Infiltrating ductular carcinoma         | 8521/3                  |
| Solid carcinoma, NOS                    | 8230/3                  |
| Invasive lobular carcinoma              |                         |
| Infiltrating lobular mixed with other types of carcinoma | 8524/3 |
| Lobular carcinoma, NOS                  | 8520/3                  |
| Mesenchymal tumours                     |                         |
| Fibrosarcoma, NOS                       | 8810/3                  |
| Haemangiosarcoma                        | 9120/3                  |
| Liposarcoma, NOS                        | 8850/3                  |
| Metaplastic carcinoma                   |                         |
| Metaplastic carcinoma, NOS              | 8575/3                  |
| Signet ring cell carcinoma              | 8490/3                  |
| Spindle cell carcinoma, NOS             | 8032/3                  |
| Squamous cell carcinoma, NOS            | 8070/3                  |
| Mucinous carcinoma                      |                         |
| Mucin-producing adenocarcinoma          | 8481/3                  |
| Mucinous adenocarcinoma                 | 8480/3                  |
| Paget’s disease                         |                         |
| Paget disease and infiltrating duct carcinoma of breast | 8541/3 |
| Paget disease and intraductal carcinoma of breast | 8543/3 |
| Paget disease, mammary                  | 8540/3                  |
| Phyllodes tumour                        |                         |
| Phyllodes tumour, malignant             | 9020/3                  |
| Rare variants                           |                         |
| Granular cell tumour, malignant         | 9580/3                  |
| Neuroendocrine carcinoma, NOS           | 8246/3                  |
| Papillary adenocarcinoma, NOS           | 8260/3                  |
| Papillary carcinoma, NOS                | 8050/3                  |
| Mixed cell adenocarcinoma               | 8323/3                  |
| Carcinoma, undifferentiated, NOS        | 8020/3                  |
| Tubular carcinoma                       | 8211/3                  |

*NOS stands for Not Otherwise Specified.*
Table 7
Breast cancer-related deaths (N = 930) by gender and year of diagnosis for the period 2005–2013. The numbers of deaths attributable to breast cancer per 1000 deaths are shown in parentheses.

| Gender | 2005    | 2006    | 2007    | 2008    | 2009    | 2010    | 2011    | 2012    | 2013    | Overall |
|--------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Female | 72 (27.8) | 81 (32.4) | 92 (35.8) | 94 (38.3) | 106 (44.1) | 110 (46.4) | 118 (45.0) | 111 (41.4) | 131 (54.9) | 915 (40.5) |
| Male   | 0 (0.0)  | 2 (0.8)  | 1 (0.4)  | 3 (1.1)  | 3 (1.1)  | 1 (0.4)  | 2 (0.7)  | 3 (1.0)  | 0 (0.0)  | 15 (0.6) |
| Total  | 72 (13.3) | 83 (16.2) | 93 (17.3) | 97 (18.7) | 109 (21.0) | 111 (21.8) | 120 (22.3) | 114 (20.1) | 131 (24.8) | 930 (19.5) |
| Time period       | Age group | Survival analysis method | 19–29 (95% CI) | 30–39 (95% CI) | 40–49 (95% CI) | 50–59 (95% CI) | 60–69 (95% CI) | 70–79 (95% CI) | 80– (95% CI) | Overall (95% CI) |
|-------------------|-----------|--------------------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------|------------------|
| Net Survival for  | 0.85 (0.66–1.04) | 0.88 (0.81–0.94) | 0.91 (0.88–0.94) | 0.87 (0.84–0.90) | 0.84 (0.81–0.88) | 0.69 (0.64–0.75) | 0.36 (0.27–0.45) | 0.82 (0.80–0.83) |            |                  |
| 2004–2008 (95% CI) | - Cohort method |            |                |                |                |                |                |                |              |                  |
| Net Survival for  | 0.80 (0.59–1.00) | 0.93 (0.90–0.97) | 0.94 (0.93–0.96) | 0.90 (0.89–0.92) | 0.89 (0.86–0.91) | 0.79 (0.75–0.82) | 0.60 (0.54–0.66) | 0.87 (0.86–0.88) |            |                  |
| 2009–2013 (95% CI) | - Period method |            |                |                |                |                |                |                |              |                  |

a CI: Confidence Interval.
b The Cohort method refers to people diagnosed in 2004–2008 (N = 2296) who were followed up at least five years after their diagnosis.
c The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 4324).
Table 9
Five-year net survival rates of all breast cancer cases by different cancer grade at diagnosis.

| Time period       | Cancer Grade                          | Survival analysis method | Net Survival for 2004–2008 (95% CI) | Net Survival for 2009–2013 (95% CI) |
|-------------------|---------------------------------------|--------------------------|-------------------------------------|-------------------------------------|
|                   | I; Well Differentiated                 |                          | 0.91 (0.86–0.95)                    | 0.92 (0.88–0.95)                    |
|                   | II; Moderately Differentiated          |                          | 0.86 (0.83–0.88)                    | 0.89 (0.87–0.90)                    |
|                   | III; Poorly Differentiated             |                          | 0.73 (0.69–0.77)                    | 0.84 (0.82–0.86)                    |
|                   | Undifferentiated/Unknown               |                          | 0.79 (0.74–0.84)                    | 0.88 (0.84–0.91)                    |
|                   | Overall                                |                          | 0.82 (0.80–0.83)                    | 0.87 (0.86–0.88)                    |

a CI: Confidence Interval.
b The Cohort method refers to people diagnosed in 2004–2008 (N = 2296) who were followed up at least five years after their diagnosis.
c The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 4324).
The ethnicity of 69 cases was ‘Unknown’. The rest (4700) were classified into Greek-Cypriots and non-Greek Cypriots.

Counts and percentages of 4700 newly diagnosed breast cancer cases of known ethnicity are presented by cancer grade (Table 2), behaviour (Table 3), stage (Table 4), and histological type at diagnosis (Table 5). Table 6 shows breast cancer histological categories and their subtypes, which have been presented previously in Table 5, and the respective International Classification of Diseases for Oncology (ICD-O-3) morphological code adopted by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) [2]. Table 7 shows breast cancer-related deaths by gender and the number of deaths attributable to breast cancer out of 1000 deaths among women and men, and in both sexes. Information on annual numbers of deaths in Cyprus were obtained from the report on mortality statistics between 2004 and 2014 [3].

Tables 8–15 present 5-year net survival rates for 2004–2008 and 2009–2013. Net survival rates are presented by age group (Table 8), cancer grade (Table 9), behaviour (Table 10), and stage at diagnosis (Table 11). The survival analysis included cases meeting the following criteria: (a) they were followed-up after their diagnosis and (b) their age was known at the time of diagnosis. The most recent entry with an updated cancer status was considered for patients recorded more than once in the registry.

Five-year net survival rates were estimated using two different approaches: cohort-based and period [4,5]. The cohort-based survival analysis involves cases diagnosed in 2004–2008 and their survival has been assessed in the 5 years (2009–2013) following the date of diagnosis. The period approach involves cases diagnosed over the period 2004–2013 but considers their survival experience in recent years i.e. over the period 2009–2013. Therefore, the period method provides more up-to-date estimates and quite closely predicts survival rates that will later be observed for cases diagnosed in 2009–2013. Net survival was estimated using the stns command in STATA version 14 [6].

### Table 10
Five-year net survival rates of all breast cancer cases by cancer behaviour at diagnosis.

| Time period       | Cancer Behaviour | Survival analysis method | Invasive (95% CI) | In situ (95% CI) | Overall (95% CI) |
|-------------------|------------------|--------------------------|-------------------|-----------------|------------------|
| Net Survival for 2004–2008 (95% CI) - Cohort method | I invasive | 0.81 (0.79–0.83) | 0.99 (0.96–1.01) | 0.82 (0.80–0.83) |
| Net Survival for 2009–2013 (95% CI) - Period method | In situ | 0.86 (0.85–0.88) | 0.98 (0.96–1.00) | 0.87 (0.86–0.88) |

a CI: Confidence Interval.
b The Cohort method refers to people diagnosed in 2004–2008 (N = 2296) who were followed up at least five years after their diagnosis.
c The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 4324).

### Table 11
Five-year net survival rates of all breast cancer cases by cancer stage at diagnosis.

| Time period       | Survival analysis method | Cancer stage | Distant metastatic (95% CI) | In situ (95% CI) | Locoregional invasive (95% CI) | Unknown (95% CI) | Overall (95% CI) |
|-------------------|--------------------------|--------------|-----------------------------|-----------------|-------------------------------|-----------------|------------------|
| Net Survival for 2004–2008 (95% CI) - Cohort method | | 0.34 (0.24–0.43) | 0.99 (0.96–1.01) | 0.85 (0.84–0.87) | 0.56 (0.46–0.66) | 0.82 (0.80–0.83) |
| Net Survival for 2009–2013 (95% CI) - Period method | | 0.49 (0.41–0.58) | 0.99 (0.98–1.00) | 0.89 (0.88–0.90) | 0.73 (0.68–0.79) | 0.87 (0.86–0.88) |

a CI: Confidence Interval.
b The Cohort method refers to people diagnosed in 2004–2008 (N = 2296) who were followed up at least five years after their diagnosis.
c The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 4324).
| **Table 12** | Five-year net survival rates of Greek-Cypriot breast cancer cases by age group. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------|
| **Time period** | **Age group**                                                                                                                   |
| **Survival analysis method** | **Net Survival for 2004–2008 (95% CI) - Cohort method** | **Net Survival for 2009–2013 (95% CI) - Period method** |
| 19–29          | 0.83 (0.61–1.04)       | 0.86 (0.68–1.03) |
| 30–39          | 0.86 (0.79–0.93)       | 0.93 (0.89–0.97) |
| 40–49          | 0.90 (0.87–0.93)       | 0.94 (0.92–0.96) |
| 50–59          | 0.88 (0.84–0.91)       | 0.91 (0.89–0.93) |
| 60–69          | 0.85 (0.81–0.89)       | 0.89 (0.87–0.91) |
| 70–79          | 0.69 (0.63–0.75)       | 0.78 (0.74–0.81) |
| 80–            | 0.37 (0.27–0.46)       | 0.59 (0.53–0.66) |
| Overall        | 0.81 (0.79–0.83)       | 0.87 (0.86–0.88) |

a CI: Confidence Interval.
b The Cohort method refers to people diagnosed in 2004–2008 (N = 1982) who were followed up at least five years after their diagnosis.
c The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 3735).
Table 13
Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer grade at diagnosis.

| Time period                      | Cancer grade                        | Survival analysis method |
|----------------------------------|-------------------------------------|--------------------------|
|                                  | I; Well Differentiated               | II; Moderately Differentiated | III; Poorly Differentiated | Undifferentiated/ Unknown | Overall     |
| Net Survival for 2004–2008 (95% CI) - Cohort method<sup>b</sup> | 0.91 (0.86–0.95) | 0.85 (0.83–0.88) | 0.73 (0.69–0.77) | 0.79 (0.74–0.85) | 0.81 (0.79–0.83) |
| Net Survival for 2009–2013 (95% CI) - Period method<sup>c</sup> | 0.92 (0.88–0.95) | 0.88 (0.87–0.90) | 0.83 (0.81–0.86) | 0.88 (0.84–0.91) | 0.87 (0.86–0.88) |

<sup>a</sup> CI: Confidence Interval.

<sup>b</sup> The Cohort method refers to people diagnosed in 2004–2008 (N = 1982) who were followed up at least five years after their diagnosis.

<sup>c</sup> The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 3735).
analyses were performed for all cases (Tables 8–11) and for cases of Greek-Cypriot ethnicity (Tables 12–15). Background mortality data used for net survival assessment were in the format of age-specific daily death rate for Cyprus and were retrieved by WHO [7]. All data were analyzed using STATA version 14 (StataCorp LP, College Station, Texas, USA).

Acknowledgement

The data used in this study were provided by the Health Monitoring Unit of the Ministry of Health of the Republic of Cyprus. The ideas and opinions expressed herein are those of the authors. Endorsement of these ideas and opinions by the Ministry of Health of the Republic of Cyprus is not intended nor should it be inferred.

Transparency document. Supporting information

Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2018.05.042.

Table 14
Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer behaviour at diagnosis.

| Time period               | Cancer behaviour | Survival analysis method | Invasive | In situ | Overall |
|---------------------------|------------------|--------------------------|----------|--------|---------|
| Net Survival for 2004–2008 (95% CI) - Cohort method\textsuperscript{a} | 0.80 (0.78–0.82) | 0.98 (0.95–1.01) | 0.81 (0.79–0.83) |
| Net Survival for 2009–2013 (95% CI) - Period method\textsuperscript{a} | 0.86 (0.85–0.87) | 0.98 (0.96–1.00) | 0.87 (0.86–0.88) |

\textsuperscript{a} CI: Confidence Interval.
\textsuperscript{b} The Cohort method refers to people diagnosed in 2004–2008 (N = 1982) who were followed up at least five years after their diagnosis.
\textsuperscript{c} The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 3735).

Table 15
Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer stage at diagnosis.

| Time period               | Cancer stage | Survival analysis method | Distant metastatic | In situ | Locoregional invasive | Unknown | Overall |
|---------------------------|--------------|--------------------------|--------------------|--------|-----------------------|---------|---------|
| Net Survival for 2004–2008 (95% CI) - Cohort method\textsuperscript{b} | 0.33 (0.24–0.43) | 0.98 (0.95–1.01) | 0.85 (0.83–0.87) | 0.50 (0.39–0.61) | 0.81 (0.79–0.83) |
| Net Survival for 2009–2013 (95% CI) - Period method\textsuperscript{b} | 0.47 (0.39–0.56) | 0.98 (0.96–1.00) | 0.89 (0.88–0.90) | 0.72 (0.66–0.78) | 0.87 (0.86–0.88) |

\textsuperscript{a} CI: Confidence Interval.
\textsuperscript{b} The Cohort method refers to people diagnosed in 2004–2008 (N = 1982) who were followed up at least five years after their diagnosis.
\textsuperscript{c} The Period method refers to survival experiences in 2009–2013 of people diagnosed between 2004–2013 (N = 3735).
References

[1] MECC-Middle East Cancer Consortium, Manual of coding and staging (https://www.moh.gov.cy/MOH/MOH.nsf/0/D6C382E728E5320FC22579C600265CDE/$file/MECC%20Manual%20of%20Coding%20and%20Staging%205.1%20July%202009.pdf). (Accessed 18 April 2018), 2009.

[2] ICD-O-3. - International Classification of Diseases for Oncology, International Agency for Research on Cancer (IARC), World Health Organization. Using ICD-O-3 online. (http://codes.iarc.fr/). (Accessed 18 April 2018), 2018.

[3] HMU-Health Monitoring Unit, Ministry of Health, Report on mortality statistics in Cyprus, 2004–2014, Nicosia, Cyprus (https://www.moh.gov.cy/Moh/MOH.nsf/All/1027CF3C182C408C22579C004186CA/$file/REPORT%20ON%20MORTALITY%20STATISTICS%20IN%20CYPRUS%202004-2014.pdf). (Accessed 18 April 2018), 2016.

[4] H. Brenner, B. Söderman, T. Hakulinen, Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370 000 cancer patients in Finland, Int. J. Epidemiol. 31 (2002) 456–462. http://dx.doi.org/10.1093/ije/31.2.456.

[5] C. Allemani, H.K. Weir, H. Carreira, R. Harewood, D. Spika, X.S. Wang, F. Bannon, et al., Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet 385 (2015) 977–1010.

[6] I. Clerc-Urmès, M. Grzebyk, G. Hédelin, Net survival estimation with stns, Stata J. 14 (2014) 87–102.

[7] WHO-World Health Organization, GHO | By category | Life tables by country - Cyprus, WHO (http://apps.who.int/gho/data/view.main.60420), (Accessed 18 April 2018), 2018.